siRNA / miRNA gene silencing Human HNSCC cell line

- Found 8888 results

Cellular assays Cell line authentication Colon cancer cell line DLD-1

Cellular assays Cell line authentication Ovarian cancer cell line ES-2

Cellular assays Cell line authentication Ovarian cancer cell line PA-1

Cellular assays Cell line authentication Cervix carcinoma cell line HeLa S3

Cellular assays Cell line authentication Renal carcinoma cell line Caki-1

Cellular assays Cell line authentication Endometrial Adenocarcinoma cell line HEC-1B

Get tips on using SNAI 1 siRNA and shRNA Plasmids (h) to perform siRNA / miRNA gene silencing Human - MDA-MB-468 SNAI 1

Products Santa Cruz Biotechnology SNAI 1 siRNA and shRNA Plasmids (h)

Get tips on using SNAI 1 siRNA and shRNA Plasmids (h) to perform siRNA / miRNA gene silencing Human - MDA-MB-231 SNAI 1

Products Santa Cruz Biotechnology SNAI 1 siRNA and shRNA Plasmids (h)
Fenozol Product

Get tips on using Fenozol to perform siRNA / miRNA gene silencing Human - BOSC23

Products A&A Biotechnology Fenozol

Short hairpin or small hairpin RNA (shRNA) is artificial RNA, which has a hairpin loop structure, and uses inherent microRNA (miRNA) machinery to silence target gene expression. This is called RNA interference (RNAi). These can be delivered via plasmids or viral/bacterial vectors. Challenges in shRNA-mediated gene silencing include: 1. Off-target silencing, 2. Packaging shRNA encoding lentivirus, and 3. Stable transduction in cells. RNAi have been designed to have anywhere from 19-27 bs, but the most effective design has 19 bp. In case commercial shRNAs are not available, potential target sites can be chosen within exon, 5’- or 3’ UTR, depending on which splice variants of the gene are desired. One should use the latest algorithms and choose at least two different sequences, targeting different regions, in order to have confidence in overcoming off-target effects. A BLAST search after selecting potential design will eliminate potential off-target sequences. For the second challenge, sequencing the vector using primers for either strand (50-100 bp upstream) is suggested, along with using enzymatic digestion on agarose gel for the vector. Next, once the shRNA-containing vector is packaged in a virus, it is important to check the viral titer before transduction. Finally, using a marker in the lentiviral vector (fluorescent protein or antibiotic resistance), along with qPCR for target gene expression can help in determining efficacy of transduction and shRNA on its target site.

RNA shRNA gene silencing Mouse Prostate cancer cell lines (DU145 and PC3) CD24 lentiviral particles

Outsource your experiment

Fill out your contact details and receive price quotes in your Inbox

  Outsource experiment
Become shareholder Discussions About us Contact Privacy Terms